Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from ADICON Holdings Limited ( (HK:9860) ) is now available.
ADICON Holdings Limited has provided an update on its proposed acquisition of 100% of the shares of Crown Bioscience International, noting that completion remains subject to several conditions precedent. These include multiple regulatory approvals and shareholder approval, and the company is working with professional advisers and authorities to secure the remaining consents.
Because key regulatory approvals are still pending, ADICON will delay sending the shareholder circular that was originally expected by April 30, 2026, and will announce a revised timeline in due course. The company cautioned that the acquisition may or may not proceed, underscoring ongoing uncertainty for shareholders and potential investors around the timing and likelihood of this major transaction closing.
The most recent analyst rating on (HK:9860) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on ADICON Holdings Limited stock, see the HK:9860 Stock Forecast page.
More about ADICON Holdings Limited
ADICON Holdings Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the healthcare and diagnostic services sector. The company focuses on expanding its capabilities and market reach through strategic acquisitions, positioning itself to broaden its service offerings and strengthen its competitive standing in regional and international markets.
Average Trading Volume: 1,089,624
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.92B
Find detailed analytics on 9860 stock on TipRanks’ Stock Analysis page.